西藏地区前列腺腺癌临床病理特征及P504s、E-cadherin、促红细胞转化特异性相关基因和雌激素受体的表达情况  

Clinicopathological Features and Expression of P504s,E-cadherin,Erythroblast Transformation-specific Related Gene and Estrogen Receptor in Prostate Adenocarcinoma in Tibet

作　　者：罗含欢[1] 霍真[2] 肖雨[2] 尼玛卓玛 王倩 达珍[1] 次仁曲珍 LUO Hanhuan;HUO Zhen;XIAO Yu;Nimazhuoma;WANG Qian;Dazhen;Cirenquzhen(Department of Pathology,Tibet Autonomous Region People’s Hospital,Lhasa 850000,China;Department of Pathology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China)

机构地区：[1]西藏自治区人民医院病理科,拉萨850000 [2]中国医学科学院北京协和医学院北京协和医院病理科,北京100730

出　　处：《中国医学科学院学报》2021年第5期761-766,共6页Acta Academiae Medicinae Sinicae

摘　　要：目的总结西藏地区前列腺腺癌患者的临床病理特征,检测P504s、E-cadherin、促红细胞转化特异性相关基因(ERG)和雌激素受体(ER)的表达情况。方法回顾性分析2013年9月至2020年9月经西藏自治区人民医院病理科确诊的15例前列腺腺癌患者的临床资料,根据2016版WHO前列腺腺癌Gleason分级和预后分组标准分级分组,全部病例均行P504s、E-cadherin、ERG和ER等免疫组织化学染色。结果15例前列腺腺癌患者年龄61~86岁,其中,12例血清前列腺特异性抗原(PSA)≥20 ng/ml,3例<20 ng/ml;穿刺活检11例,经尿道前列腺电切1例,前列腺根治性切除3例。前列腺腺癌预后分组结果显示:≤3级组5例,4级组4例,5级组6例。15例(100%)P504s、E-cadherin和PSA免疫组织化学检测均为阳性,1例1/15(7%)ERG阳性,所有病例P63、ER和CK34βE12均为阴性。13例患者有随访资料,随访2~48个月,2例采取手术全前列腺切除,11例采用非手术治疗,均健在;2例失访。结论前列腺腺癌在西藏地区相对少见,联合应用多项免疫组织化学标记物可以提高诊断的准确性。在现有病理确诊的病例中,西藏地区4、5级组病例相对多见。P504s和E-cadherin在西藏地区前列腺腺癌中高表达,ERG低表达,ER不表达。Objective To investigate the clinicopathological features and immunohistochemical expression of P504s,E-cadherin,erythroblast transformation-specific related gene(ERG)and estrogen receptor(ER)in prostate adenocarcinoma in Tibet.Methods The clinical data of 15 patients with prostate adenocarcinoma diagnosed by the Department of Pathology of Tibet Autonomous Region People’s Hospital from September 2013 to September 2020 were analyzed retrospectively.All patients were assigned to prognostic grade groups based on Gleason score according to the WHO 2016 criteria.Immunostaining of P504s,E-cadherin,ERG,and ER was performed.Results The age of all 15 patients ranged from 61 to 86 years.The serum prostate specific antigen(PSA)concentration was≥20 ng/ml in 12 patients and<20 ng/ml in 3 patients.Among the 15 patients,11 underwent needle biopsy,1 transurethral resection of the prostate,and 3 radical prostatectomy.Prognostic grouping results revealed 5 cases in grade groups 1-3,4 cases in grade group 4,and 6 cases in grade group 5.Immunohistochemistrically,15 cases(100%)were positive for P504s,E-cadherin and PSA;one case(7%)was positive for ERG;all cases were negative for P63,ER and CK34βE12.Thirteen cases were followed up for 2-48 months,with 2 cases treated with total prostatectomy and 11 cases with non-surgical treatment.Two cases were lost to follow-up.Conclusions Prostate adenocarcinoma is rare relatively in Tibet.The accuracy of diagnosis can be improved by using multiple immunohistochemical markers.The cases of grades 4 and 5 by pathological confirmed are relatively common in Tibet.P504s and E-cadherin are highly expressed in prostate adenocarcinoma patients in Tibet,while ERG presents low expression,ER is unexpressed.

关 键 词：西藏 前列腺腺癌 病理特征 分级分组 免疫组织化学 

分 类 号：R737.25[医药卫生—肿瘤]